Psychotherapy with Psilocybin for Depression: Systematic Review
Behavioral Sciences – March 31, 2023
Source: OpenAlex
Summary
Psilocybin offers a powerful new approach in medicine for mental health, rapidly improving depressive symptoms for months. Eight clinical psychology studies highlight its potential, even for treatment-resistant depression affecting 280 million people globally, a significant economic burden. Administered with psychotherapist support, this psychedelic, a naturally occurring alkaloid, fosters deep introspection and well-being after just one or two doses, influencing behavior through neurotransmitter pathways. This represents a significant development in psychiatry and drug studies.
Abstract
Depression is a common mental health issue that affects 280 million people in the world with a high mortality rate, as well as being a leading cause of disability. Psychopharmacological therapies with psychedelics, particularly those with psilocybin, are showing promising potential for the treatment of depression, among other conditions. Some of their benefits include a rapid and exponential improvement in depressive symptoms and an increased sense of well-being that can last for months after the treatment, as well as a greater development of introspective capacity. The aim of this project was to provide experimental evidence about therapeutic procedures along with psilocybin for the treatment of major depressive disorder. The project highlights eight studies that examined this condition. Some of them dealt with treatment-resistant depression while others dealt with depression due to a life-threatening disease such as cancer. These publications affirm the efficiency of the psilocybin therapy for depression, with only one or two doses in conjunction with psychological support during the process.